UC Davis Scores Big Cash To Tackle Firefighters’ Cancer Crisis
UC Davis won state grants to study cancer among firefighters, pairing wearables and blood tests with air sampling to hunt for hazardous exposures and biomarkers.
Bay Area Biotech Ends Year With Jaw-Dropping $4 Billion Stock Play
San Francisco Business Times found the Bay Area’s largest year‑end stock sale was about $4 billion in biotech, as local drug developers leaned on secondary offerings to raise cash. Terns was among the biggest raises in December.
Tri-Valley Teen Tech Whizzes Turn Homework Into Police Drones And Medical AI
Tri‑Valley high schoolers are building drones, AI and satellite maps that have already drawn police, funder and NASA attention. Their work shows how local STEM investment can move prototypes into pilots.
Ninth Circuit Slaps Apple Over App Store Defiance, Reopens Fee Fight
The Ninth Circuit largely upheld a contempt finding against Apple but rejected an absolute ban on off‑App Store commissions, sending the fee dispute back to the district court.
Tiny SF AI Upstart Wins Court Block on OpenAI 'IO' Name Grab
A Ninth Circuit panel in San Francisco upheld a TRO blocking OpenAI and Jony Ive from using 'io' to market hardware similar to startup iyO's voice‑only computer.
Oakland Health Giant Kaiser Slapped With $46M Payout Over Patient Data Leak
Kaiser agreed to a preliminary $46 million settlement after tracking pixels on its sites and apps may have shared member data with tech vendors. The deal affects millions and faces a court fairness hearing.
MIT Simulation Says Al Can Already Do Nearly 12% of U.S. Work, Worth $1.2 Trillion
MIT’s new Iceberg Index finds AI can already perform work equal to about 11.7% of U.S. wage value — roughly $1.2 trillion — and the exposure is spread beyond tech hubs.
Magnetic Tides' kTMP Wins FDA Breakthrough, Eyes Stroke Trials
Berkeley startup Magnetic Tides says its kilohertz brain‑stimulation method boosted cortical excitability in early testing, won FDA Breakthrough status and is enrolling patients in trials. Early safety signals are encouraging but larger clinical studies are next.












